<DOC>
	<DOCNO>NCT00553098</DOCNO>
	<brief_summary>This phase II trial study fludarabine phosphate total-body irradiation without alemtuzumab follow donor stem cell transplant see well work treat patient immunodeficiency nonmalignant inherited disorder . Giving chemotherapy , fludarabine phosphate , monoclonal antibody alemtuzumab , radiation therapy donor stem cell transplant help stop growth abnormal cell . It may also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain abnormal cell .</brief_summary>
	<brief_title>Alemtuzumab , Fludarabine Phosphate , Total-Body Irradiation Followed Donor Stem Cell Transplant Treating Patients With Immunodeficiency Other Nonmalignant Inherited Disorders</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Improve donor chimerism level patient inherit nonmalignant disorder undergo hematopoietic cell transplantation ( HCT ) use reduce intensity condition regimen either addition Campath ( alemtuzumab ) slightly high dose total-body irradiation ( TBI ) . SECONDARY OBJECTIVES : I . Decrease incidence severity acute chronic graft-versus-host disease ( GVHD ) use marrow stem cell source Campath . II . Assess disease response follow HCT . III . Immune reconstitution follow HCT . IV . Incidence infection . V. Overall survival . VI . Percent patient cluster differentiation ( CD ) 33/CD19 donor chimerism &gt; 50 % . OUTLINE : CONDITIONING REGIMEN : Patients life-threatening viral fungal infection within 1 month plan hematopoietic cell transplantation ( HCT ) receive alemtuzumab intravenously ( IV ) 6 hour day -10 fludarabine phosphate IV 30 minute day -4 -2 . They also undergo low-dose TBI day 0 . Patients hemophagocytic lymphohistiocytosis ( HLH ) , immune dysregulation polyendocrinopathy enteropathy X-linked ( IPEX ) syndrome , DiGeorge syndrome , life-threatening viral fungal infection within 1 month plan HCT receive fludarabine phosphate IV 30 minute day -4 -2 undergo 2 low dos TBI day 0 . HEMATOPOIETIC CELL TRANSPLANTATION : Patients undergo HCT day 0 . IMMUNOSUPPRESSION : Patients receive cyclosporine IV orally ( PO ) 2-3 time daily begin day -3 continue day 100 follow taper day 180 . They also receive mycophenolate mofetil IV PO 3 time daily begin day 0 continue day 40 follow taper day 96 . After completion HCT , patient follow day 84 , 6 , 12 , 18 24 month post-transplantation , year 3 year .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Primary immunodeficiency disorder nonmalignant inherit disease ( except aplastic anemia Fanconi anemia ) treatable allogeneic HCT Patients preexist medical condition factor render high risk regimen relate toxicity ineligible conventional myeloablative HCT Donors : Related donor human leukocyte antigen ( HLA ) genotypically identical least one haplotype may genotypically phenotypically identical serological typing HLAA , B , C , allele level DRB1 DQB1 ; related donor must match single allele mismatch HLAA , B , C ( high resolution available time donor selection ) match DRB1 DQB1 deoxyribonucleic acid ( DNA ) type Donors : Unrelated donor prospectively : Matched HLAA , B , C , DRB1 DQB1 DNA type high resolution routinely available time donor selection Only single allele disparity allow HLAA , B , C define high resolution typing ( mismatch DRB1 DQB1 allow ) Patients Aplastic anemia Fanconi anemia Patients metabolic storage disease severe central nervous system ( CNS ) involvement disease , define intelligence quotient ( IQ ) score &lt; 70 Cardiac ejection fraction &lt; 30 % , unable obtain ejection fraction , shorten fraction &lt; 26 % ) multigated acquisition ( MUGA ) scan cardiac echo , symptomatic coronary artery disease , cardiac failure require therapy ; patient history , current cardiac disease evaluate appropriate cardiac study and/or cardiology consult ; patient shorten fraction &lt; 26 % may enrol approve cardiologist Poorly control hypertension despite antihypertensive medication Patients clinical laboratory evidence liver disease need evaluate cause liver disease , clinical severity term liver function degree portal hypertension ; patient exclude find : fulminant liver failure , cirrhosis liver evidence portal hypertension , bridge fibrosis , alcoholic hepatitis , esophageal varix , history bleed esophageal varix , hepatic encephalopathy , uncorrectable hepatic synthetic dysfunction evidence prolongation prothrombin time , ascites related portal hypertension , bacterial fungal liver abscess , biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3mg/dl , symptomatic biliary disease ( Patients allow protocol liver problem gastroenterology approves patient HCT ) Patients positive human immunodeficiency virus ( HIV ) Females pregnant breastfeed Fertile men woman unwilling use contraceptive HCT 12 month posttreatment Patients fungal pneumonia radiological progression receipt amphotericin formulation moldactive azoles great 1 month eligible protocol ( either regimen A B ) Donors : Identical twin Donors : Pregnancy Donors : HIV positive Donors : A positive antidonor cytotoxic cross match absolute donor exclusion Donors : If patient homozygous particular locus , mismatch locus allow due isolate graft rejection vector , i.e. , patient A*0101 donor A*0101 , A*0201 ; mismatch may increase risk graft rejection ; patient donor pair homozygous mismatch locus , consider twoHLA antigen mismatch , i.e. , patient A*0101 donor A*0201 , type mismatch allow Donor : Donor &lt; 6 month old , &gt; 75 year old</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>54 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>